

2011 Lancaster/Berks County Court Rules

Click Here or call 877-256-2472

The Legal Intelligencer

An **ALM** Web site


30 Day **FREE** Web Trial

The Legal Intelligencer

THE OLDEST LAW JOURNAL IN THE UNITED STATES



This Site | Law.com Network | Legal Web



- Home
- News
- Firms & Lawyers
- Courts
- Judges
- Surveys/Lists
- Columns
- Verdicts
- Public Notices
- Advertise
- Subscribe

- Large Firm News
- Small Firms
- In-House
- People In The News
- Search Attorney Directory
- Professional Announcements
- Young Lawyers
- Pro Bono

Home > Allocatur Denial May Mean Hundreds of HRT Cases Remain in Phila.

Font Size: + -

Allocatur Denial May Mean Hundreds of HRT Cases Remain in Phila.

[Amaris Elliott-Egel](#) | [Contact](#) | [All Articles](#)

The Legal Intelligencer | July 11, 2011

- Print
- Share
- Email
- Reprints & Permissions
- Post a Comment



Pennsylvania Superior Court Judge Correale Stevens



Judge Mary Jane Bowes

The state Supreme Court's denial Thursday of a drug manufacturer's request to hear more than a dozen hormone-replacement therapy tort cases could keep hundreds of cases on the Philadelphia Common Pleas Court's dockets.

When the state Superior Court overturned Philadelphia Common Pleas Court Judge Allan L. Tereshko's grant of summary judgment in favor of Wyeth Pharmaceuticals and Pharmacia & Upjohn in 14 consolidated cases, the intermediate court said it is a question of fact, not a question of law, whether the plaintiffs could have known

at the time of their diagnoses with breast cancer that the alleged cause of their cancer was their HRT prescriptions.

Tobi Millrood, plaintiffs' liaison counsel for the HRT program and of Pogust Braslow & Millrood in Conshohocken, Pa., said that his co-counsel and he estimate that 50 to 60 percent of the 1,000 cases left in the Philadelphia HRT mass tort program involved the discovery rule.

The manufacturers of HRT drugs argued that the plaintiffs' two-year statute of limitations ran from the day they were diagnosed with breast cancer, while the plaintiffs argued that an alleged link between HRT drugs and breast cancer was not known prior to the release of the Women's Health Initiative study on July 9, 2002. The study received wide-ranging notoriety because the study was discontinued out of the concern that the study participants taking HRT were showing a higher rate of breast cancer than the control group, among other reasons.

With the Supreme Court's affirmation, the decision by Superior Court President Judge Correale F. Stevens, Judge Mary Jane Bowes and Senior Judge James J. Fitzgerald could become the most cited pharmaceutical negligence case in Pennsylvania, Millrood said.

"It will provide a bedrock principle that the discovery rule is applicable in Pennsylvania and is a question of fact that is left for the jury," Millrood said.

The decision has wider implications in pharmaceutical cases because "many times the cause of an injury is hidden from the physician and plaintiff," Millrood said. "It's not until some kind of significant scientific development or some study or some announcement comes out that the plaintiff can learn the cause. At that point it kicks in the discovery rule."

But Millrood said that he didn't think Pfizer, which now owns both Wyeth and Pharmacia & Upjohn, was holding out hope that the Superior Court was going to be reversed because he said the trial court's opinion was an "outlier" and the Superior Court's opinion was in line with other appellate rulings on how the discovery rule should be applied.

Advertisement

one MORE reason

Now from LexisNexis®
ALM® content you can't find on Westlaw®.

Stay informed with ALM local, regional and national legal news.

LexisNexis®

Find similar content

- Firms mentioned ▶
- Companies, agencies mentioned ▶
- Key categories ▶
- Most viewed stories ▼
- 1 With Uptick in Suits, Litigation Defense Lawyers in Demand **FREE WITH REGISTRATION**
- 2 Judge Refuses Stay in \$30 Mil. Copyright Case **FREE WITH REGISTRATION**
- 3 Wolf Block Litigation Continues; Former Chairman Responds **FREE WITH REGISTRATION**
- 4 3rd Circuit Upholds Most of FCC's Media Ownership Rules **FREE WITH REGISTRATION**
- 5 Phila. Board of Ethics Postpones Lobbying Law Enforcement **FREE WITH REGISTRATION**

Advertisement

"Given the way the Supreme Court and the appellate courts are interpreting this, we would have been a little surprised if they took up something that didn't have a new wrinkle to it," Millrood said.

Tereshko granted defense motions for summary judgment in all of the cases because, he said in his opinions, there was sufficient public information at the time all of the plaintiffs were diagnosed with breast cancer for the plaintiffs to learn that there was a risk of developing breast cancer from taking HRT drugs. He also said that many of the plaintiffs were on notice of a link between HRT and their cancer because their doctors told them to stop using HRT after their diagnoses.

However, the three-judge Superior Court panel agreed with the plaintiffs' theory, finding that the discovery rule may have tolled their statute of limitations until the release of the WHI study. The court said it is jurors, not judges, who must decide if the plaintiffs made reasonable efforts to discover that the alleged cause of their breast cancer may have stemmed from third-party drugmakers.

Defendant Upjohn made Provera, a synthetic form of the hormone progesterone. Wyeth made Premarin, an estrogen drug, and Prempro, a combination estrogen-synthetic progesterone drug. Both pharmaceutical companies are now subsidiaries of drugmaker Pfizer.

The Supreme Court denied allocatur in the cases of *Coleman v. Wyeth*, *Medwid v. Wyeth*, *Weinberger v. Wyeth*, *Reed v. Wyeth*, *Taw v. Wyeth*, *Morales v. Wyeth*, *Lenzi v. Wyeth*, *Schirm v. Wyeth*, *Fleming-Crain v. Wyeth*, *Honaker v. Wyeth*, *Hansen v. Wyeth*, *Blaylock v. Wyeth*, *Manalo v. Wyeth* and *Hess v. Wyeth*.

Coleman is Pennsylvania's second precedent-setting decision regarding HRT litigation.

"While we are disappointed with the court's decision, it is a procedural ruling and not one on the merits of these 14 consolidated cases," Pfizer's subsidiaries, Wyeth and Pharmacia & Upjohn, said in a statement. "This merely returns the cases to a lower court for further proceeding to determine the merits of the plaintiffs' lawsuits."

Further, the company said that it has a "strong record of success in defending cases," including prevailing on the issue of statute of limitations in a ruling Thursday by a federal court in Mississippi.

Finally, the company said that HRT is an important treatment option for women with menopausal symptoms and that many risk factors are associated with breast cancer.

Robert C. Heim of Dechert is Pfizer's counsel, and the defendant liaison counsel to Philadelphia's HRT mass tort program. •

[Subscribe to The Legal Intelligencer](#)

Print Share Email Reprints & Permissions Post a Comment

The Legal Intelligencer

The 2011 Philadelphia County Court Rules are Here!

CLICK HERE or call 877-256-2472 to order.

lawjobs.com

TOP JOBS

Chester County, PA - Litigation Associate
Fox Rothschild LLP
Exton, Pennsylvania

Philadelphia, PA_Sr. Litigation Associate/
Counsel
CONFIDENTIAL SEARCH
Philadelphia, PA

**MORE JOBS
POST A JOB**

Advertisement

The Legal Intelligencer

2011 Construction Law Special Section

Publish Date: August 2

Click Here for More Information
or call Don Chalphin at 215-557-2359

From the Law.com Network

AMERICAN LAWYER



For The Am Law 200, a Time of Rebuilding

The 2011 Am Law 200 - Revenue Per Lawyer (Top 20)

THE NATIONAL LAW JOURNAL



Federal Judge Tosses Major Portion of Toyota Shareholder Suit

9th Circuit Tells Obama Administration to State Its Position on 'Don't Ask'

LTN LAW TECHNOLOGY NEWS



kCura Plans E-Discovery App Market

LexisNexis Evolves Concordance E-Discovery

Deloitte.

Introducing the Deloitte Discovery Infocenter

Discovery Infocenter
A highly efficient discovery process translates to a high quality response. Access featured discovery articles, whitepapers, interviews, and webcasts to improve your discovery process and performance. Learn More.

THE RECORD



9th Circuit Hints Speech Protects V of Unearned Med

AOC Recommend Courts Cut Budget year, 15% in 2012

THE LEGAL INTELLIGENCER

HELP & INFORMATION CENTER [Customer Service](#) | [Submit An Article](#) | [Submit A Verdict](#) | [Letters to the Editor](#) | [PICS Order Form](#)

THE LEGAL INTELLIGENCER.COM [About Us](#) | [Contact Us](#) | [Privacy Policy](#) | [Terms & Conditions](#)

SUBSCRIBE [Click Here For Subscription Options](#)

ADVERTISE [Place An Ad](#) | [View Jobs](#) | [View Real Estate Listings](#) | [View Experts](#) | [Professional Announcements](#) | [Editorial Calendar](#)

OTHER RESOURCES [Events](#) | [Reprints & Permissions](#) | [Legal Products](#) | [Retail Marketplace](#) | [Public Notices](#) | [RSS Feed](#)

the LAW.COM network

Advertise

LAW.COM

[Newswire](#)
[Special Reports](#)
[International News](#)
[Small Firms](#)
[Lists, Surveys & Rankings](#)
[Legal Blogs](#)

ALM NATIONAL

[The American Lawyer](#)
[The Am Law Litigation Daily](#)
[Corporate Counsel](#)
[Law Technology News](#)
[Minority Law Journal](#)
[The National Law Journal](#)

ALM REGIONAL

[Connecticut Law Tribune](#)
[Daily Business Review \(FL\)](#)
[Delaware Law Weekly](#)
[Daily Report \(GA\)](#)
[The Legal Intelligencer \(PA\)](#)
[New Jersey Law Journal](#)
[New York Law Journal](#)
[GC New York](#)
[New York Lawyer](#)
[The Recorder \(CA\)](#)
[Texas Lawyer](#)

DIRECTORIES

[ALM Experts](#)
[LegalTech® Directory](#)
[In-House Law Departments at the Top 500 Companies](#)
[New York's Women Leaders in the Law](#)
[Corporate Counsel: Best Lawyers® Annual Guides](#)
[The American Lawyer: Best Lawyers® Annual Guides](#)
[The National Law Journal Leadership Profiles](#)

BOOKS & NEWSLETTERS

[Best-Selling Books](#)
[Publication E-Alerts](#)
[Law Journal Newsletters](#)
[LawCatalog](#)
[Law Journal Press Online](#)

RESEARCH

[ALM Legal Intelligence](#)
[Court Reporters](#)
[MA 3000](#)
[Verdict Search](#)
[ALM Experts](#)
[Legal Dictionary](#)
[Smart Litigator](#)

EVENTS & CONFERENCES

[ALM Events](#)
[LegalTech®](#)
[Virtual LegalTech®](#)
[Virtual Events](#)
[Webinars & Online Events](#)
[Insight Information](#)

REPRINTS

[Reprints](#)

ONLINE CLE

[CLE Center](#)

CAREER

[Lawjobs](#)

[About ALM](#) | [About Law.com](#) | [Customer Support](#) | [Reprints](#) | [Privacy Policy](#) | [Terms & Conditions](#)
Copyright 2011. ALM Media Properties, LLC. All rights reserved.

